IL6 and infection: Consistent with the lack of effect on BR15 infection, AbII treatment did not significantly alter the levels of IL-1β, IL-6, IL-10, CCL2 (MCP-1), CCL5 (RANTES), or CXCL8 (IL-8) in BR15-infected cells (Figure 4E).